CASI Pharmaceuticals, Inc. (CASI) 10-Year Financial Performance & Capital Metrics

CASI • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsHematologic Oncology

AboutCASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase I/IIa trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome. Its product pipeline also comprises CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; and Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors. The company has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland.Show more

Revenue $29M -15.8%
EBITDA -$37M -74.8%
Net Income -$39M -45.7%
EPS (Diluted) -2.56 -26.7%
Gross Margin 39.06% -34.0%
EBITDA Margin -130.67% -107.5%
Operating Margin -138.84% -87.6%
Net Margin -137.57% -73.0%
ROE -301.8% -410.3%
ROIC -153% -101.3%
Debt/Equity 11.96 +1261.0%
Interest Coverage -45.49

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 47.2%
✓Healthy dividend yield of 4.5%

✗Weaknesses

✗High debt to equity ratio of 12.0x
✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Weak momentum: RS Rating 9 (bottom 9%)
✗Shares diluted 14.8% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y103.24%

5Y47.19%

3Y-1.84%

TTM21.72%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-59.58%

EPS CAGR

10Y-

5Y-

3Y-

TTM-41.7%

ROCE

10Y Avg-20.22%

5Y Avg-50.01%

3Y Avg-55.64%

Latest-104.59%

Peer Comparison

Hematologic Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
INCYIncyte Corporation	20.66B	105.24	701.60	14.76%	24.69%	25.55%	1.21%	0.01
TGTXTG Therapeutics, Inc.	4.88B	30.71	204.73	40.8%	13.31%	21.87%		1.14
AGIOAgios Pharmaceuticals, Inc.	1.62B	27.80	2.39	36.07%	-8.96%	-31.24%		0.04
CLRBCellectar Biosciences, Inc.	15.48M	3.65	-0.09			-200.99%		0.03
CASICASI Pharmaceuticals, Inc.	21.37M	1.04	-0.41	-15.77%	-183.93%	-301.8%		11.96
VORVor Biopharma Inc.	308.06M	14.06	-0.41			-94.52%		0.33
FATEFate Therapeutics, Inc.	121.12M	1.05	-0.64	-78.55%	-21.87%	-66.69%		0.27
KPTIKaryopharm Therapeutics Inc.	121.95M	6.66	-0.71	-0.55%	-87.43%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	47.71K	0	0	0	4.13M	15.14M	30.17M	43.11M	33.88M	28.54M
Revenue Growth %	1.01%	-1%	-	-	-	2.67%	0.99%	0.43%	-0.21%	-0.16%
Cost of Goods Sold+	6.27K	66.45K	117.78K	1.67M	3.94M	9.51M	12.56M	15.83M	13.83M	17.39M
COGS % of Revenue	0.13%	-	-	-	0.95%	0.63%	0.42%	0.37%	0.41%	0.61%
Gross Profit+	41.44K	-66.45K	-117.78K	-1.67M	196K	5.63M	17.61M	27.28M	20.05M	11.15M
Gross Margin %	0.87%	-	-	-	0.05%	0.37%	0.58%	0.63%	0.59%	0.39%
Gross Profit Growth %	1.55%	-2.6%	-0.77%	-13.19%	1.12%	27.74%	2.13%	0.55%	-0.26%	-0.44%
Operating Expenses+	7.19M	9.42M	10.75M	26.5M	40.19M	58.41M	59.13M	53.77M	45.13M	50.77M
OpEx % of Revenue	150.78%	-	-	-	9.73%	3.86%	1.96%	1.25%	1.33%	1.78%
Selling, General & Admin	3.12M	4.78M	3.16M	18M	30.44M	27.48M	38.41M	37.77M	41.84M	41.44M
SG&A % of Revenue	65.36%	-	-	-	7.37%	1.81%	1.27%	0.88%	1.23%	1.45%
Research & Development	4.08M	4.65M	7.6M	8.51M	9.75M	11.47M	14.42M	16M	9.86M	8.92M
R&D % of Revenue	85.42%	-	-	-	2.36%	0.76%	0.48%	0.37%	0.29%	0.31%
Other Operating Expenses	0	0	0	0	0	19.47M	6.3M	0	-6.57M	407K
Operating Income+	7.15M	9.42M	-10.75M	-26.5M	-39.99M	-52.78M	-41.52M	-26.49M	-25.08M	-39.62M
Operating Margin %	149.91%	-	-	-	-9.68%	-3.49%	-1.38%	-0.61%	-0.74%	-1.39%
Operating Income Growth %	-0.73%	0.32%	-2.14%	-1.47%	-0.51%	-0.32%	0.21%	0.36%	0.05%	-0.58%
EBITDA+	7.22M	9.49M	-10.63M	-24.83M	-37.84M	-50.82M	-39.7M	-24.07M	-21.34M	-37.29M
EBITDA Margin %	151.34%	-	-	-	-9.16%	-3.36%	-1.32%	-0.56%	-0.63%	-1.31%
EBITDA Growth %	-0.72%	0.31%	-2.12%	-1.34%	-0.52%	-0.34%	0.22%	0.39%	0.11%	-0.75%
D&A (Non-Cash Add-back)	68.38K	66.45K	117.78K	1.67M	2.15M	1.96M	1.81M	2.42M	3.74M	2.33M
EBIT	-7.12M	-9.42M	-10.76M	-27.46M	-39.58M	-33.31M	-35.22M	-26.49M	-25.28M	-37.2M
Net Interest Income+	-81.53K	-26.09K	1.01K	39.99K	1.06M	866K	321K	127K	614K	-332K
Interest Income	922	7.72K	15.98K	48.2K	1.06M	866K	321K	189K	614K	539K
Interest Expense	82.45K	33.81K	14.98K	8.21K	0	0	0	62K	0	871K
Other Income/Expense	-54.02K	-32.88K	-18.88K	-967.57K	-5.37M	5.27M	5.67M	-11.79M	-1.21M	1.55M
Pretax Income+	-7.21M	-9.45M	-10.77M	-27.47M	-45.36M	-47.51M	-35.84M	-38.28M	-26.29M	-38.07M
Pretax Margin %	-151.04%	-	-	-	-10.98%	-3.14%	-1.19%	-0.89%	-0.78%	-1.33%
Income Tax+	82.45K	33.81K	14.98K	0	0	0	0	1.98M	-81K	1.19M
Effective Tax Rate %	1%	1%	1%	1%	1%	1.02%	1.02%	1.07%	1.02%	1.03%
Net Income+	-7.21M	-9.45M	-10.77M	-27.47M	-45.36M	-48.29M	-36.65M	-41.01M	-26.94M	-39.26M
Net Margin %	-151.04%	-	-	-	-10.98%	-3.19%	-1.21%	-0.95%	-0.8%	-1.38%
Net Income Growth %	0.72%	-0.31%	-0.14%	-1.55%	-0.65%	-0.06%	0.24%	-0.12%	0.34%	-0.46%
Net Income (Continuing)	-7.21M	-9.45M	-10.77M	-27.47M	-45.36M	-47.51M	-35.84M	-40.26M	-26.21M	-39.26M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	20.67M	22.03M	23.46M	22.36M	0	0
EPS (Diluted)+	-2.22	-1.69	-1.75	-3.24	-4.80	-4.37	-2.69	-3.01	-2.02	-2.56
EPS Growth %	0.76%	0.24%	-0.04%	-0.85%	-0.48%	0.09%	0.38%	-0.12%	0.33%	-0.27%
EPS (Basic)	-2.22	-1.69	-1.75	-3.24	-4.80	-4.37	-2.69	-3.01	-2.02	-2.56
Diluted Shares Outstanding	3.24M	5.59M	6.15M	8.48M	9.59M	11.05M	13.61M	13.65M	13.36M	15.34M
Basic Shares Outstanding	3.24M	5.59M	6.15M	8.48M	9.59M	11.05M	13.61M	13.65M	13.36M	15.34M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	5.57M	27.45M	43.81M	92.56M	61.5M	74.03M	61.97M	73.42M	59.34M	39.58M
Cash & Short-Term Investments	5.13M	27.09M	43.49M	85.12M	54.25M	66.37M	48.57M	51.34M	30.77M	16.09M
Cash Only	5.13M	27.09M	43.49M	84.2M	53.62M	57.06M	38.7M	47.11M	17.08M	13.47M
Short-Term Investments	0	0	0	912.2K	625K	9.31M	9.87M	4.22M	13.69M	2.62M
Accounts Receivable	0	0	0	0	1.29M	4.64M	9.8M	12.97M	10.14M	15.35M
Days Sales Outstanding	-	-	-	-	114.24	111.98	118.61	109.85	109.22	196.27
Inventory	0	0	0	283K	4.54M	1.36M	1.91M	6.14M	15.88M	5.25M
Days Inventory Outstanding	-	-	-	61.82	421.3	52.06	55.43	141.55	419.12	110.23
Other Current Assets	438.23K	355.89K	322.49K	911.81K	0	0	0	2.98M	2.56M	2.89M
Total Non-Current Assets+	256.97K	264.08K	1.29M	20.85M	41.13M	53.71M	76.33M	22.81M	15.92M	13.9M
Property, Plant & Equipment	218.8K	229.59K	1.05M	1.75M	9.69M	10.76M	21.82M	13.23M	11.63M	11.36M
Fixed Asset Turnover	0.22x	-	-	-	0.43x	1.41x	1.38x	3.26x	2.91x	2.51x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	18.78M	16.89M	13.21M	12.2M	1.06M	1.84M	238K
Long-Term Investments	0	0	0	0	14.04M	29.44M	40.13M	7.46M	1.68M	1.72M
Other Non-Current Assets	38.17K	34.48K	242.02K	310.02K	504K	299K	2.18M	1.06M	771K	587K
Total Assets+	5.83M	27.71M	45.1M	113.41M	102.63M	127.73M	138.3M	96.23M	75.27M	53.67M
Asset Turnover	0.01x	-	-	-	0.04x	0.12x	0.22x	0.45x	0.45x	0.53x
Asset Growth %	-0.48%	3.76%	0.63%	1.51%	-0.1%	0.24%	0.08%	-0.3%	-0.22%	-0.29%
Total Current Liabilities+	1.05M	1.32M	5.06M	3.87M	7.95M	7.98M	13.19M	17M	16.73M	36.45M
Accounts Payable	884.1K	1.06M	2.09M	968K	5.11M	3.26M	4.79M	3.29M	4.44M	2.72M
Days Payables Outstanding	51.43K	5.85K	6.47K	211.45	474.27	125.15	139.2	75.85	117.15	57.15
Short-Term Debt	0	0	0	1.5M	0	1.29M	2.17M	0	0	18.39M
Deferred Revenue (Current)	4.09K	0	0	0	0	0	0	1000K	1000K	1000K
Other Current Liabilities	0	0	2.23M	944	-1.18M	0	-7.62M	0	0	10.31M
Current Ratio	5.29x	20.86x	8.65x	23.89x	7.74x	9.28x	4.70x	4.32x	3.55x	1.09x
Quick Ratio	5.29x	20.86x	8.65x	23.82x	7.17x	9.11x	4.56x	3.96x	2.60x	0.94x
Cash Conversion Cycle	-	-	-	-	61.28	38.88	34.83	175.55	411.19	249.35
Total Non-Current Liabilities+	10.86M	5.61M	1.5M	73.59K	1.02M	16.18M	17.15M	12.3M	34.38M	15.37M
Long-Term Debt	1.46M	1.49M	1.5M	0	0	0	0	0	18.89M	0
Capital Lease Obligations	0	0	0	0	1.02M	965K	1.1M	476K	1.62M	2.54M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	9.4M	4.12M	0	73.59K	0	12.87M	13.22M	11.82M	13.87M	12.84M
Total Liabilities	11.91M	6.93M	6.56M	3.95M	8.97M	24.16M	30.34M	29.3M	51.1M	51.82M
Total Debt+	1.46M	1.49M	1.5M	1.5M	2.2M	3.2M	4.33M	1.34M	21.24M	22.14M
Net Debt	-3.67M	-25.6M	-41.99M	-82.71M	-51.42M	-53.87M	-34.37M	-45.77M	4.16M	8.67M
Debt / Equity	-	0.07x	0.04x	0.01x	0.02x	0.03x	0.04x	0.02x	0.88x	11.96x
Debt / EBITDA	0.20x	0.16x	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-0.51x	-2.70x	-	-	-	-	-	-	-	-
Interest Coverage	86.74x	278.65x	-717.90x	-3229.10x	-	-	-	-427.27x	-	-45.49x
Total Equity+	-6.09M	20.78M	38.54M	109.46M	93.67M	103.57M	107.96M	66.93M	24.16M	1.85M
Equity Growth %	-13.42%	4.41%	0.85%	1.84%	-0.14%	0.11%	0.04%	-0.38%	-0.64%	-0.92%
Book Value per Share	-1.88	3.72	6.27	12.92	9.76	9.38	7.93	4.90	1.81	0.12
Total Shareholders' Equity	-6.09M	20.78M	38.54M	109.46M	73M	81.54M	84.5M	44.57M	24.16M	1.85M
Common Stock	325.25K	602.76K	699.01K	953.67K	979K	1.24M	1.4M	1K	1K	2K
Retained Earnings	-432.48M	-441.93M	-452.7M	-478.94M	-523.91M	-570.5M	-605.64M	-637.16M	-660.82M	-700.08M
Treasury Stock	-8.03M	-8.03M	-8.03M	-8.03M	-8.03M	-8.03M	-8.03M	-9.33M	-9.6M	-9.6M
Accumulated OCI	-293.53K	-262.02K	-372.27K	-1.23M	-2.73M	589K	1.95M	-703K	-1.2M	-1.77M
Minority Interest	0	0	0	0	20.67M	22.03M	23.46M	22.36M	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-5.51M	-6.02M	-6.4M	-28.58M	-23.24M	-25.89M	-26.84M	-21.09M	-19.97M	-29.22M
Operating CF Margin %	-115.56%	-	-	-	-5.63%	-1.71%	-0.89%	-0.49%	-0.59%	-1.02%
Operating CF Growth %	-0.38%	-0.09%	-0.06%	-3.46%	0.19%	-0.11%	-0.04%	0.21%	0.05%	-0.46%
Net Income	-7.21M	-9.45M	-10.77M	-27.47M	-45.36M	-47.51M	-35.84M	-40.26M	-26.94M	-39.26M
Depreciation & Amortization	68.38K	66.45K	117.78K	1.67M	2.15M	1.96M	1.81M	2.42M	3.74M	2.33M
Stock-Based Compensation	1.54M	3M	650.44K	6.12M	7.31M	7.82M	7.77M	7.01M	7.22M	1.31M
Deferred Taxes	-27.51K	-5.67K	19.89K	325.46K	1.24M	-3.94M	-5.2M	0	0	0
Other Non-Cash Items	74.95K	26.31K	7.48K	553.57K	6.97M	19.1M	7.83M	16.39M	3.83M	5.63M
Working Capital Changes	36K	348.04K	3.57M	-9.78M	4.45M	-3.32M	-3.22M	-6.65M	-7.82M	771K
Change in Receivables	23.73K	0	0	0	-1.29M	-3.35M	-5.16M	-3.17M	2.83M	-5.21M
Change in Inventory	-4.63M	0	0	-283K	-4.41M	3.19M	-551K	-4.23M	-9.74M	5.83M
Change in Payables	129.47K	180.53K	849.37K	-1.1M	4M	-1.54M	1.49M	1.07M	1.15M	-1.72M
Cash from Investing+	-25.4K	-64.79K	-934.7K	-21.77M	-28.06M	-20.72M	-20.69M	31.16M	-9.67M	11.24M
Capital Expenditures	-25.4K	-223.23K	-934.7K	-21.77M	-14.02M	-19.33M	-15.5M	-5.61M	-204K	-223K
CapEx % of Revenue	0.53%	-	-	-	3.39%	1.28%	0.51%	0.13%	0.01%	0.01%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-25.4K	158.45K	0	20.64M	-6.97M	-1.31M	7.03M	6.44M	-2.04M	483K
Cash from Financing+	0	28.05M	23.73M	92.27M	22.05M	47.15M	29.64M	-3.27M	-907K	15.43M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	-738K	-718K
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	-96.51K	-462.84K	4.02M	23.36M	805K	-2.02M	0	0	1.15M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-5.54M	-6.25M	-7.34M	-50.36M	-37.26M	-45.21M	-42.34M	-26.7M	-22.21M	-29.46M
FCF Margin %	-116.09%	-	-	-	-9.02%	-2.99%	-1.4%	-0.62%	-0.66%	-1.03%
FCF Growth %	-0.24%	-0.13%	-0.17%	-5.86%	0.26%	-0.21%	0.06%	0.37%	0.17%	-0.33%
FCF per Share	-1.71	-1.12	-1.19	-5.94	-3.88	-4.09	-3.11	-1.96	-1.66	-1.92
FCF Conversion (FCF/Net Income)	0.77x	0.64x	0.59x	1.04x	0.51x	0.54x	0.73x	0.51x	0.74x	0.74x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	1.81M	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-128.65%	-36.31%	-37.12%	-44.66%	-48.96%	-34.66%	-46.9%	-59.14%	-301.8%
Return on Invested Capital (ROIC)	-	-	-	-170.59%	-86.93%	-86.1%	-50.51%	-41.94%	-76.02%	-153%
Gross Margin	86.85%	-	-	-	4.74%	37.2%	58.38%	63.28%	59.19%	39.06%
Net Margin	-15104.01%	-	-	-	-1098.09%	-318.92%	-121.5%	-95.14%	-79.51%	-137.57%
Debt / Equity	-	0.07x	0.04x	0.01x	0.02x	0.03x	0.04x	0.02x	0.88x	11.96x
Interest Coverage	86.74x	278.65x	-717.90x	-3229.10x	-	-	-	-427.27x	-	-45.49x
FCF Conversion	0.77x	0.64x	0.59x	1.04x	0.51x	0.54x	0.73x	0.51x	0.74x	0.74x
Revenue Growth	101.09%	-100%	-	-	-	266.52%	99.25%	42.89%	-21.41%	-15.77%

Revenue by Segment

	2019
E V O M E L A	4.1M
E V O M E L A Growth	-

Frequently Asked Questions

Growth & Financials

CASI Pharmaceuticals, Inc. (CASI) reported $26.8M in revenue for fiscal year 2024. This represents a 1283% increase from $1.9M in 2011.

CASI Pharmaceuticals, Inc. (CASI) saw revenue decline by 15.8% over the past year.

CASI Pharmaceuticals, Inc. (CASI) reported a net loss of $49.4M for fiscal year 2024.

Dividend & Returns

Yes, CASI Pharmaceuticals, Inc. (CASI) pays a dividend with a yield of 4.50%. This makes it attractive for income-focused investors.

CASI Pharmaceuticals, Inc. (CASI) has a return on equity (ROE) of -301.8%. Negative ROE indicates the company is unprofitable.

CASI Pharmaceuticals, Inc. (CASI) had negative free cash flow of $29.5M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

CASI Pharmaceuticals, Inc. (CASI) 10-Year Financial Performance & Capital Metrics

CASI • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsHematologic Oncology

Revenue $29M -15.8%
EBITDA -$37M -74.8%
Net Income -$39M -45.7%
EPS (Diluted) -2.56 -26.7%
Gross Margin 39.06% -34.0%
EBITDA Margin -130.67% -107.5%
Operating Margin -138.84% -87.6%
Net Margin -137.57% -73.0%
ROE -301.8% -410.3%
ROIC -153% -101.3%
Debt/Equity 11.96 +1261.0%
Interest Coverage -45.49

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 47.2%
✓Healthy dividend yield of 4.5%

✗Weaknesses

✗High debt to equity ratio of 12.0x
✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Weak momentum: RS Rating 9 (bottom 9%)
✗Shares diluted 14.8% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y103.24%

5Y47.19%

3Y-1.84%

TTM21.72%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-59.58%

EPS CAGR

10Y-

5Y-

3Y-

TTM-41.7%

ROCE

10Y Avg-20.22%

5Y Avg-50.01%

3Y Avg-55.64%

Latest-104.59%

Peer Comparison

Hematologic Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
INCYIncyte Corporation	20.66B	105.24	701.60	14.76%	24.69%	25.55%	1.21%	0.01
TGTXTG Therapeutics, Inc.	4.88B	30.71	204.73	40.8%	13.31%	21.87%		1.14
AGIOAgios Pharmaceuticals, Inc.	1.62B	27.80	2.39	36.07%	-8.96%	-31.24%		0.04
CLRBCellectar Biosciences, Inc.	15.48M	3.65	-0.09			-200.99%		0.03
CASICASI Pharmaceuticals, Inc.	21.37M	1.04	-0.41	-15.77%	-183.93%	-301.8%		11.96
VORVor Biopharma Inc.	308.06M	14.06	-0.41			-94.52%		0.33
FATEFate Therapeutics, Inc.	121.12M	1.05	-0.64	-78.55%	-21.87%	-66.69%		0.27
KPTIKaryopharm Therapeutics Inc.	121.95M	6.66	-0.71	-0.55%	-87.43%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	47.71K	0	0	0	4.13M	15.14M	30.17M	43.11M	33.88M	28.54M
Revenue Growth %	1.01%	-1%	-	-	-	2.67%	0.99%	0.43%	-0.21%	-0.16%
Cost of Goods Sold+	6.27K	66.45K	117.78K	1.67M	3.94M	9.51M	12.56M	15.83M	13.83M	17.39M
COGS % of Revenue	0.13%	-	-	-	0.95%	0.63%	0.42%	0.37%	0.41%	0.61%
Gross Profit+	41.44K	-66.45K	-117.78K	-1.67M	196K	5.63M	17.61M	27.28M	20.05M	11.15M
Gross Margin %	0.87%	-	-	-	0.05%	0.37%	0.58%	0.63%	0.59%	0.39%
Gross Profit Growth %	1.55%	-2.6%	-0.77%	-13.19%	1.12%	27.74%	2.13%	0.55%	-0.26%	-0.44%
Operating Expenses+	7.19M	9.42M	10.75M	26.5M	40.19M	58.41M	59.13M	53.77M	45.13M	50.77M
OpEx % of Revenue	150.78%	-	-	-	9.73%	3.86%	1.96%	1.25%	1.33%	1.78%
Selling, General & Admin	3.12M	4.78M	3.16M	18M	30.44M	27.48M	38.41M	37.77M	41.84M	41.44M
SG&A % of Revenue	65.36%	-	-	-	7.37%	1.81%	1.27%	0.88%	1.23%	1.45%
Research & Development	4.08M	4.65M	7.6M	8.51M	9.75M	11.47M	14.42M	16M	9.86M	8.92M
R&D % of Revenue	85.42%	-	-	-	2.36%	0.76%	0.48%	0.37%	0.29%	0.31%
Other Operating Expenses	0	0	0	0	0	19.47M	6.3M	0	-6.57M	407K
Operating Income+	7.15M	9.42M	-10.75M	-26.5M	-39.99M	-52.78M	-41.52M	-26.49M	-25.08M	-39.62M
Operating Margin %	149.91%	-	-	-	-9.68%	-3.49%	-1.38%	-0.61%	-0.74%	-1.39%
Operating Income Growth %	-0.73%	0.32%	-2.14%	-1.47%	-0.51%	-0.32%	0.21%	0.36%	0.05%	-0.58%
EBITDA+	7.22M	9.49M	-10.63M	-24.83M	-37.84M	-50.82M	-39.7M	-24.07M	-21.34M	-37.29M
EBITDA Margin %	151.34%	-	-	-	-9.16%	-3.36%	-1.32%	-0.56%	-0.63%	-1.31%
EBITDA Growth %	-0.72%	0.31%	-2.12%	-1.34%	-0.52%	-0.34%	0.22%	0.39%	0.11%	-0.75%
D&A (Non-Cash Add-back)	68.38K	66.45K	117.78K	1.67M	2.15M	1.96M	1.81M	2.42M	3.74M	2.33M
EBIT	-7.12M	-9.42M	-10.76M	-27.46M	-39.58M	-33.31M	-35.22M	-26.49M	-25.28M	-37.2M
Net Interest Income+	-81.53K	-26.09K	1.01K	39.99K	1.06M	866K	321K	127K	614K	-332K
Interest Income	922	7.72K	15.98K	48.2K	1.06M	866K	321K	189K	614K	539K
Interest Expense	82.45K	33.81K	14.98K	8.21K	0	0	0	62K	0	871K
Other Income/Expense	-54.02K	-32.88K	-18.88K	-967.57K	-5.37M	5.27M	5.67M	-11.79M	-1.21M	1.55M
Pretax Income+	-7.21M	-9.45M	-10.77M	-27.47M	-45.36M	-47.51M	-35.84M	-38.28M	-26.29M	-38.07M
Pretax Margin %	-151.04%	-	-	-	-10.98%	-3.14%	-1.19%	-0.89%	-0.78%	-1.33%
Income Tax+	82.45K	33.81K	14.98K	0	0	0	0	1.98M	-81K	1.19M
Effective Tax Rate %	1%	1%	1%	1%	1%	1.02%	1.02%	1.07%	1.02%	1.03%
Net Income+	-7.21M	-9.45M	-10.77M	-27.47M	-45.36M	-48.29M	-36.65M	-41.01M	-26.94M	-39.26M
Net Margin %	-151.04%	-	-	-	-10.98%	-3.19%	-1.21%	-0.95%	-0.8%	-1.38%
Net Income Growth %	0.72%	-0.31%	-0.14%	-1.55%	-0.65%	-0.06%	0.24%	-0.12%	0.34%	-0.46%
Net Income (Continuing)	-7.21M	-9.45M	-10.77M	-27.47M	-45.36M	-47.51M	-35.84M	-40.26M	-26.21M	-39.26M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	20.67M	22.03M	23.46M	22.36M	0	0
EPS (Diluted)+	-2.22	-1.69	-1.75	-3.24	-4.80	-4.37	-2.69	-3.01	-2.02	-2.56
EPS Growth %	0.76%	0.24%	-0.04%	-0.85%	-0.48%	0.09%	0.38%	-0.12%	0.33%	-0.27%
EPS (Basic)	-2.22	-1.69	-1.75	-3.24	-4.80	-4.37	-2.69	-3.01	-2.02	-2.56
Diluted Shares Outstanding	3.24M	5.59M	6.15M	8.48M	9.59M	11.05M	13.61M	13.65M	13.36M	15.34M
Basic Shares Outstanding	3.24M	5.59M	6.15M	8.48M	9.59M	11.05M	13.61M	13.65M	13.36M	15.34M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	5.57M	27.45M	43.81M	92.56M	61.5M	74.03M	61.97M	73.42M	59.34M	39.58M
Cash & Short-Term Investments	5.13M	27.09M	43.49M	85.12M	54.25M	66.37M	48.57M	51.34M	30.77M	16.09M
Cash Only	5.13M	27.09M	43.49M	84.2M	53.62M	57.06M	38.7M	47.11M	17.08M	13.47M
Short-Term Investments	0	0	0	912.2K	625K	9.31M	9.87M	4.22M	13.69M	2.62M
Accounts Receivable	0	0	0	0	1.29M	4.64M	9.8M	12.97M	10.14M	15.35M
Days Sales Outstanding	-	-	-	-	114.24	111.98	118.61	109.85	109.22	196.27
Inventory	0	0	0	283K	4.54M	1.36M	1.91M	6.14M	15.88M	5.25M
Days Inventory Outstanding	-	-	-	61.82	421.3	52.06	55.43	141.55	419.12	110.23
Other Current Assets	438.23K	355.89K	322.49K	911.81K	0	0	0	2.98M	2.56M	2.89M
Total Non-Current Assets+	256.97K	264.08K	1.29M	20.85M	41.13M	53.71M	76.33M	22.81M	15.92M	13.9M
Property, Plant & Equipment	218.8K	229.59K	1.05M	1.75M	9.69M	10.76M	21.82M	13.23M	11.63M	11.36M
Fixed Asset Turnover	0.22x	-	-	-	0.43x	1.41x	1.38x	3.26x	2.91x	2.51x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	18.78M	16.89M	13.21M	12.2M	1.06M	1.84M	238K
Long-Term Investments	0	0	0	0	14.04M	29.44M	40.13M	7.46M	1.68M	1.72M
Other Non-Current Assets	38.17K	34.48K	242.02K	310.02K	504K	299K	2.18M	1.06M	771K	587K
Total Assets+	5.83M	27.71M	45.1M	113.41M	102.63M	127.73M	138.3M	96.23M	75.27M	53.67M
Asset Turnover	0.01x	-	-	-	0.04x	0.12x	0.22x	0.45x	0.45x	0.53x
Asset Growth %	-0.48%	3.76%	0.63%	1.51%	-0.1%	0.24%	0.08%	-0.3%	-0.22%	-0.29%
Total Current Liabilities+	1.05M	1.32M	5.06M	3.87M	7.95M	7.98M	13.19M	17M	16.73M	36.45M
Accounts Payable	884.1K	1.06M	2.09M	968K	5.11M	3.26M	4.79M	3.29M	4.44M	2.72M
Days Payables Outstanding	51.43K	5.85K	6.47K	211.45	474.27	125.15	139.2	75.85	117.15	57.15
Short-Term Debt	0	0	0	1.5M	0	1.29M	2.17M	0	0	18.39M
Deferred Revenue (Current)	4.09K	0	0	0	0	0	0	1000K	1000K	1000K
Other Current Liabilities	0	0	2.23M	944	-1.18M	0	-7.62M	0	0	10.31M
Current Ratio	5.29x	20.86x	8.65x	23.89x	7.74x	9.28x	4.70x	4.32x	3.55x	1.09x
Quick Ratio	5.29x	20.86x	8.65x	23.82x	7.17x	9.11x	4.56x	3.96x	2.60x	0.94x
Cash Conversion Cycle	-	-	-	-	61.28	38.88	34.83	175.55	411.19	249.35
Total Non-Current Liabilities+	10.86M	5.61M	1.5M	73.59K	1.02M	16.18M	17.15M	12.3M	34.38M	15.37M
Long-Term Debt	1.46M	1.49M	1.5M	0	0	0	0	0	18.89M	0
Capital Lease Obligations	0	0	0	0	1.02M	965K	1.1M	476K	1.62M	2.54M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	9.4M	4.12M	0	73.59K	0	12.87M	13.22M	11.82M	13.87M	12.84M
Total Liabilities	11.91M	6.93M	6.56M	3.95M	8.97M	24.16M	30.34M	29.3M	51.1M	51.82M
Total Debt+	1.46M	1.49M	1.5M	1.5M	2.2M	3.2M	4.33M	1.34M	21.24M	22.14M
Net Debt	-3.67M	-25.6M	-41.99M	-82.71M	-51.42M	-53.87M	-34.37M	-45.77M	4.16M	8.67M
Debt / Equity	-	0.07x	0.04x	0.01x	0.02x	0.03x	0.04x	0.02x	0.88x	11.96x
Debt / EBITDA	0.20x	0.16x	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-0.51x	-2.70x	-	-	-	-	-	-	-	-
Interest Coverage	86.74x	278.65x	-717.90x	-3229.10x	-	-	-	-427.27x	-	-45.49x
Total Equity+	-6.09M	20.78M	38.54M	109.46M	93.67M	103.57M	107.96M	66.93M	24.16M	1.85M
Equity Growth %	-13.42%	4.41%	0.85%	1.84%	-0.14%	0.11%	0.04%	-0.38%	-0.64%	-0.92%
Book Value per Share	-1.88	3.72	6.27	12.92	9.76	9.38	7.93	4.90	1.81	0.12
Total Shareholders' Equity	-6.09M	20.78M	38.54M	109.46M	73M	81.54M	84.5M	44.57M	24.16M	1.85M
Common Stock	325.25K	602.76K	699.01K	953.67K	979K	1.24M	1.4M	1K	1K	2K
Retained Earnings	-432.48M	-441.93M	-452.7M	-478.94M	-523.91M	-570.5M	-605.64M	-637.16M	-660.82M	-700.08M
Treasury Stock	-8.03M	-8.03M	-8.03M	-8.03M	-8.03M	-8.03M	-8.03M	-9.33M	-9.6M	-9.6M
Accumulated OCI	-293.53K	-262.02K	-372.27K	-1.23M	-2.73M	589K	1.95M	-703K	-1.2M	-1.77M
Minority Interest	0	0	0	0	20.67M	22.03M	23.46M	22.36M	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-5.51M	-6.02M	-6.4M	-28.58M	-23.24M	-25.89M	-26.84M	-21.09M	-19.97M	-29.22M
Operating CF Margin %	-115.56%	-	-	-	-5.63%	-1.71%	-0.89%	-0.49%	-0.59%	-1.02%
Operating CF Growth %	-0.38%	-0.09%	-0.06%	-3.46%	0.19%	-0.11%	-0.04%	0.21%	0.05%	-0.46%
Net Income	-7.21M	-9.45M	-10.77M	-27.47M	-45.36M	-47.51M	-35.84M	-40.26M	-26.94M	-39.26M
Depreciation & Amortization	68.38K	66.45K	117.78K	1.67M	2.15M	1.96M	1.81M	2.42M	3.74M	2.33M
Stock-Based Compensation	1.54M	3M	650.44K	6.12M	7.31M	7.82M	7.77M	7.01M	7.22M	1.31M
Deferred Taxes	-27.51K	-5.67K	19.89K	325.46K	1.24M	-3.94M	-5.2M	0	0	0
Other Non-Cash Items	74.95K	26.31K	7.48K	553.57K	6.97M	19.1M	7.83M	16.39M	3.83M	5.63M
Working Capital Changes	36K	348.04K	3.57M	-9.78M	4.45M	-3.32M	-3.22M	-6.65M	-7.82M	771K
Change in Receivables	23.73K	0	0	0	-1.29M	-3.35M	-5.16M	-3.17M	2.83M	-5.21M
Change in Inventory	-4.63M	0	0	-283K	-4.41M	3.19M	-551K	-4.23M	-9.74M	5.83M
Change in Payables	129.47K	180.53K	849.37K	-1.1M	4M	-1.54M	1.49M	1.07M	1.15M	-1.72M
Cash from Investing+	-25.4K	-64.79K	-934.7K	-21.77M	-28.06M	-20.72M	-20.69M	31.16M	-9.67M	11.24M
Capital Expenditures	-25.4K	-223.23K	-934.7K	-21.77M	-14.02M	-19.33M	-15.5M	-5.61M	-204K	-223K
CapEx % of Revenue	0.53%	-	-	-	3.39%	1.28%	0.51%	0.13%	0.01%	0.01%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-25.4K	158.45K	0	20.64M	-6.97M	-1.31M	7.03M	6.44M	-2.04M	483K
Cash from Financing+	0	28.05M	23.73M	92.27M	22.05M	47.15M	29.64M	-3.27M	-907K	15.43M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	-738K	-718K
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	-96.51K	-462.84K	4.02M	23.36M	805K	-2.02M	0	0	1.15M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-5.54M	-6.25M	-7.34M	-50.36M	-37.26M	-45.21M	-42.34M	-26.7M	-22.21M	-29.46M
FCF Margin %	-116.09%	-	-	-	-9.02%	-2.99%	-1.4%	-0.62%	-0.66%	-1.03%
FCF Growth %	-0.24%	-0.13%	-0.17%	-5.86%	0.26%	-0.21%	0.06%	0.37%	0.17%	-0.33%
FCF per Share	-1.71	-1.12	-1.19	-5.94	-3.88	-4.09	-3.11	-1.96	-1.66	-1.92
FCF Conversion (FCF/Net Income)	0.77x	0.64x	0.59x	1.04x	0.51x	0.54x	0.73x	0.51x	0.74x	0.74x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	1.81M	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-128.65%	-36.31%	-37.12%	-44.66%	-48.96%	-34.66%	-46.9%	-59.14%	-301.8%
Return on Invested Capital (ROIC)	-	-	-	-170.59%	-86.93%	-86.1%	-50.51%	-41.94%	-76.02%	-153%
Gross Margin	86.85%	-	-	-	4.74%	37.2%	58.38%	63.28%	59.19%	39.06%
Net Margin	-15104.01%	-	-	-	-1098.09%	-318.92%	-121.5%	-95.14%	-79.51%	-137.57%
Debt / Equity	-	0.07x	0.04x	0.01x	0.02x	0.03x	0.04x	0.02x	0.88x	11.96x
Interest Coverage	86.74x	278.65x	-717.90x	-3229.10x	-	-	-	-427.27x	-	-45.49x
FCF Conversion	0.77x	0.64x	0.59x	1.04x	0.51x	0.54x	0.73x	0.51x	0.74x	0.74x
Revenue Growth	101.09%	-100%	-	-	-	266.52%	99.25%	42.89%	-21.41%	-15.77%

Revenue by Segment

	2019
E V O M E L A	4.1M
E V O M E L A Growth	-

Frequently Asked Questions

Growth & Financials

CASI Pharmaceuticals, Inc. (CASI) reported $26.8M in revenue for fiscal year 2024. This represents a 1283% increase from $1.9M in 2011.

CASI Pharmaceuticals, Inc. (CASI) saw revenue decline by 15.8% over the past year.

CASI Pharmaceuticals, Inc. (CASI) reported a net loss of $49.4M for fiscal year 2024.

Dividend & Returns

Yes, CASI Pharmaceuticals, Inc. (CASI) pays a dividend with a yield of 4.50%. This makes it attractive for income-focused investors.

CASI Pharmaceuticals, Inc. (CASI) has a return on equity (ROE) of -301.8%. Negative ROE indicates the company is unprofitable.

CASI Pharmaceuticals, Inc. (CASI) had negative free cash flow of $29.5M in fiscal year 2024, likely due to heavy capital investments.